BMS Trumpets Breakthrough For Phase III-Bound IPF Drug
Strong Showing For LPA1 Antagonist
Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.
You may also be interested in...
FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure
MATTERHORN’s failure did not surprise analysts, but it’s likely the end of the road for roxadustat in the US market. The focus instead has shifted to FibroGen’s IPF asset pamrevlumab.
AbbVie Gains New Immunology Antibody Platform With DJS Buy
Deal Snapshot: AbbVie will acquire the privately-held UK antibody developer with preclinical assets.
Boehringer Bids To Go Beyond Slowing IPF
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.